One of the most sophisticated clinical trials combines chemotherapy, bevacizumab, avelumab, ALT-803 (IL-15 super agonist), aNK (allogenic human NK-92 cell line, expressing CD16 and IL-2), and GI-4000 (a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras) with the NANT pancreatic cancer vaccine (ETBX-011) containing a replication-defective adenoviral vector encoding a CEA epitope Ad5-CEA(6D), used for pancreatic cancer (NCT03136406). This evidence concerns the gene IL15 and pancreatic neoplasm.